A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

March 15, 2028

Conditions

B-cell LymphomaAcute Myeloid LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

XS-04 tablet

Each treatment cycle is 28 days, with continuous oral administration, twice daily.

Trial Locations (4)

RECRUITING

Beijing Cancer Hospital, Beijing

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangdong

RECRUITING

Affiliated Hospital of Hebei University, Hebei

NOT_YET_RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei